Item Response Theory as an Efficient Tool to Describe a Heterogeneous Clinical Rating Scale in De Novo Idiopathic Parkinson’s Disease Patients

PurposeThis manuscript aims to precisely describe the natural disease progression of Parkinson’s disease (PD) patients and evaluate approaches to increase the drug effect detection power.MethodsAn item response theory (IRT) longitudinal model was built to describe the natural disease progression of 423 de novo PD patients followed during 48 months while taking into account the heterogeneous nature of the MDS-UPDRS. Clinical trial simulations were then used to compare drug effect detection power from IRT and sum of item scores based analysis under different analysis endpoints and drug effects.ResultsThe IRT longitudinal model accurately describes the evolution of patients with and without PD medications while estimating different progression rates for the subscales. When comparing analysis methods, the IRT-based one consistently provided the highest power.ConclusionIRT is a powerful tool which enables to capture the heterogeneous nature of the MDS-UPDRS.

[1]  J. Jankovic,et al.  Functional decline in Parkinson disease. , 2001, Archives of neurology.

[2]  K. Marder,et al.  Progression of parkinsonian signs in Parkinson disease. , 1999, Archives of neurology.

[3]  N. Jetté,et al.  The prevalence of Parkinson's disease: A systematic review and meta‐analysis , 2014, Movement disorders : official journal of the Movement Disorder Society.

[4]  The Unified Parkinson's Disease Rating Scale (UPDRS): Status and recommendations , 2003, Movement disorders : official journal of the Movement Disorder Society.

[5]  Joel S. Perlmutter,et al.  Assessment of Parkinson Disease Manifestations , 2009, Current protocols in neuroscience.

[6]  K. Chaudhuri,et al.  Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment , 2009, The Lancet Neurology.

[7]  Andrew C. Hooker,et al.  Improved Utilization of ADAS-Cog Assessment Data Through Item Response Theory Based Pharmacometric Modeling , 2014, Pharmaceutical Research.

[8]  W. Poewe,et al.  Effects of rasagiline on the progression of nonmotor scores of the MDS‐UPDRS , 2015, Movement disorders : official journal of the Movement Disorder Society.

[9]  F. Baker The basics of item response theory , 1985 .

[10]  A. Lees,et al.  A clinicopathologic study of 100 cases of Parkinson's disease. , 1993, Archives of neurology.

[11]  J. Jankovic,et al.  The heterogeneity of Parkinson's disease , 1985, Neurology.

[12]  J. Nutt,et al.  Disease Progression and Pharmacodynamics in Parkinson Disease – Evidence for Functional Protection with Levodopa and Other Treatments , 2006, Journal of Pharmacokinetics and Pharmacodynamics.

[13]  Hansjürgen Bratzke,et al.  Stages in the development of Parkinson’s disease-related pathology , 2004, Cell and Tissue Research.

[14]  J. Nutt,et al.  Parkinson's disease , 2004, The Lancet.

[15]  Ss Beal,et al.  NONMEM User’s Guides. (1989–2009) , 2009 .

[16]  M. Karlsson,et al.  Modeling a Composite Score in Parkinson’s Disease Using Item Response Theory , 2017, The AAPS Journal.

[17]  Mats O. Karlsson,et al.  Comparison of proportional and differential odds models for mixed-effects analysis of categorical data , 2008, Journal of Pharmacokinetics and Pharmacodynamics.

[18]  J. Jankovic,et al.  Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS): Scale presentation and clinimetric testing results , 2008, Movement disorders : official journal of the Movement Disorder Society.

[19]  M. Frasier,et al.  Parkinson's Disease Biomarkers: Resources for Discovery and Validation , 2014, Neuropsychopharmacology.

[20]  J. Nutt,et al.  Disease progress and response to treatment as predictors of survival, disability, cognitive impairment and depression in Parkinson's disease. , 2012, British journal of clinical pharmacology.

[21]  A. Stiggelbout,et al.  Systematic evaluation of rating scales for impairment and disability in Parkinson's disease , 2002, Movement disorders : official journal of the Movement Disorder Society.

[22]  M. Hoehn,et al.  Parkinsonism , 1967, Neurology.

[23]  J. Nutt,et al.  Progression of motor and nonmotor features of Parkinson's disease and their response to treatment. , 2012, British journal of clinical pharmacology.